Humotech named its first board of managers. One seat went to a physiatrist.

Humotech, a developer of wearable device platforms for prosthetics, orthotics, and exoskeletons, named five people to its first formal board of managers this week.

Traci Dralle, CEO and founder of Dralle Advisors, which advises O&P companies on commercialization and growth strategy, chairs the board. Josh Caputo, PhD, Humotech’s founder and CEO, also holds a seat. The remaining three: Wes Moschetto, a health tech executive with more than two decades of experience in healthcare technology, diagnostics, and access to care; Jo Hartoyo, a technology executive focused on digital transformation across healthcare and high-tech sectors; and Ronald M. Yarab Jr., MD, a physiatrist with more than 30 years in physical medicine and rehabilitation, musculoskeletal medicine, and neuromuscular medicine.

The clinical seat

Physiatrists are not the most common board members at device platform companies. They are, however, the physicians most consistently involved in prosthetic prescription, functional goal-setting, and post-amputation rehabilitation planning. When a company builds tools designed to help researchers and clinicians compare prosthetic components systematically, having that physician perspective inside governance rather than just in an advisory capacity shapes how the company defines what a successful platform outcome looks like.

Yarab’s background spans clinical practice and clinical practice management. That combination is specific: it covers both what happens in the exam room and how a practice runs well enough to actually use new tools.

What Humotech builds

The company develops wearable device platforms that allow researchers and clinicians to test, measure, and compare different prosthetic, orthotic, and exoskeletal components in controlled conditions. The research output from these platforms can inform clinical protocols, support coverage arguments with comparative outcome data, and help practitioners move beyond manufacturer specifications when evaluating device options.

That evidence pipeline matters in a practical way. Prior authorization and coverage decisions increasingly require documented functional outcomes. A platform that generates usable data in that form sits upstream of the clinical and insurance decisions that determine what devices people can actually get. More rigorous, independently generated outcome data makes those arguments easier to build.

What this means

A governance board with this composition asks different questions than a research advisory committee would. Dralle’s and Moschetto’s backgrounds point toward broader market deployment, not just academic licensing. Whether that translates to faster availability of Humotech tools at community O&P practices remains to be seen. This announcement does not describe a product launch, a new insurance contract, or a rollout timeline. It formalizes a leadership structure.

The next question worth tracking: what does commercial growth look like in practice for a research platform company in this space? That answer will show up in what Humotech ships and where it ships to, not in the board roster.

This article covers an industry governance announcement. It does not constitute medical, device, or benefits advice.